Results 91 to 100 of about 2,820 (114)
Some of the next articles are maybe not open access.
Intravenous Golimumab in the Treatment of Juvenile Idiopathic Arthritis and Its Associated Uveitis
Ocular Immunology and InflammationTo demonstrate the efficacy and safety of intravenous golimumab infusion in treating juvenile idiopathic arthritis-associated anterior uveitis.This study was a retrospective observation case series. Electronic records of patients diagnosed with juvenile idiopathic arthritis-associated anterior uveitis who received intravenous golimumab infusion were ...
Sohum Sheth, Arash Maleki
exaly +3 more sources
Value in Health, 2020
Evaluate the effects of intravenous golimumab 2 mg/kg on multiple domains of health-related quality of life (HRQoL) in adult patients with active psoriatic arthritis (PsA).In this phase III, randomized, double-blinded, placebo-controlled study, adults with active PsA were randomized in a 1:1 ratio to receive intravenous (IV) infusions of placebo (n ...
M Elaine Husni +2 more
exaly +3 more sources
Evaluate the effects of intravenous golimumab 2 mg/kg on multiple domains of health-related quality of life (HRQoL) in adult patients with active psoriatic arthritis (PsA).In this phase III, randomized, double-blinded, placebo-controlled study, adults with active PsA were randomized in a 1:1 ratio to receive intravenous (IV) infusions of placebo (n ...
M Elaine Husni +2 more
exaly +3 more sources
Clinical Therapeutics, 2012
The pharmacokinetics of golimumab, a human monoclonal antibody that inhibits the activity of tumor necrosis factor α, after a single subcutaneous (SC) or intravenous (IV) administration have been previously studied.The purpose of this study was to assess the pharmacokinetics of golimumab after multiple SC or IV administrations in patients with active ...
Yanli Zhuang +2 more
exaly +3 more sources
The pharmacokinetics of golimumab, a human monoclonal antibody that inhibits the activity of tumor necrosis factor α, after a single subcutaneous (SC) or intravenous (IV) administration have been previously studied.The purpose of this study was to assess the pharmacokinetics of golimumab after multiple SC or IV administrations in patients with active ...
Yanli Zhuang +2 more
exaly +3 more sources
Intravenous golimumab in rheumatoid arthritis
Expert Review of Clinical Immunology, 2014Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile.
Marc D, Cohen, Edward C, Keystone
openaire +2 more sources
Annals of the Rheumatic Diseases, 2015
Objectives To describe the safety profile of IV GLM in RA (MTX nonresponders) from the Ph3 GO-FURTHER trial. AE rates of interest are indirectly compared to those observed in the SC GLM GO-FORWARD trial in a similar pt population. Methods In GO-FURTHER, pts with active RA despite MTX were randomized to MTX + IV PBO or GLM 2mg/kg at wks 0, 4, and ...
R. Westhovens +7 more
openaire +1 more source
Objectives To describe the safety profile of IV GLM in RA (MTX nonresponders) from the Ph3 GO-FURTHER trial. AE rates of interest are indirectly compared to those observed in the SC GLM GO-FORWARD trial in a similar pt population. Methods In GO-FURTHER, pts with active RA despite MTX were randomized to MTX + IV PBO or GLM 2mg/kg at wks 0, 4, and ...
R. Westhovens +7 more
openaire +1 more source
FRI0038 Pharmacodynamic Effect of Intravenous Golimumab by Messenger RNA Expression Profiling
Annals of the Rheumatic Diseases, 2014Background Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease resulting in joint inflammation and damage. Despite the current therapies available, only a small percentage of RA pts achieve remission. To improve care and treatment for RA pts, a deeper understanding of the mechanisms that drive disease and response to therapy are ...
Y. Cherkas +3 more
openaire +1 more source
Annals of the Rheumatic Diseases, 2014
Objectives To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods 592 pts with active RA (≥6/66 SJC, ≥6/68 TJC, CRP≥1.0mg/dL, RF and/or anti-CCP positive) despite ≥3 months of MTX (15-25mg/wk) participated in this multicenter, randomized, double-blind, placebo (PBO)-controlled study.
M.E. Weinblatt +7 more
openaire +1 more source
Objectives To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods 592 pts with active RA (≥6/66 SJC, ≥6/68 TJC, CRP≥1.0mg/dL, RF and/or anti-CCP positive) despite ≥3 months of MTX (15-25mg/wk) participated in this multicenter, randomized, double-blind, placebo (PBO)-controlled study.
M.E. Weinblatt +7 more
openaire +1 more source